|1.||Unger, Miriam: 1 article (10/2013)|
|2.||Vessières, Anne: 1 article (10/2013)|
|3.||Lecomte, Sophie: 1 article (10/2013)|
|4.||Policar, Clotilde: 1 article (10/2013)|
|5.||Deniset-Besseau, Ariane: 1 article (10/2013)|
|6.||Dazzi, Alexandre: 1 article (10/2013)|
|7.||Sandt, Christophe: 1 article (10/2013)|
|8.||Clède, Sylvain: 1 article (10/2013)|
|9.||Hirschmugl, Carol: 1 article (10/2013)|
|10.||Saint-Fort, Rénette: 1 article (10/2013)|
09/01/1969 - "In the case of mestranol, this might be a combination of an effect upon basal metabolic rate (enhancing hypothermia) and a direct effect on the liver. "
09/01/1969 - "This suggested that the ability to potentiate hypothermia was not the sole mechanism by which the effects of pentobarbitone were enhanced by mestranol.6. It is concluded these steroids alter the duration of action of pentobarbitone (and hexobarbitone) by changing the rate of barbiturate metabolism. "
09/01/1969 - "1. Mestranol (oestrogen) prolonged, whilst lynestrenol (progestin) reduced, the duration of pentobarbitone and hexobarbitone sleep in mice, whilst the effects of barbitone were not altered.2. The effects of these steroids on pentobarbitone sleep were dose-related, did not show tachyphylaxis, and produced optimal effects after only 4 days pretreatment.3. The effects of lynestrenol were abolished by SKF 525A, whilst those of mestranol were markedly potentiated, suggesting a different mechanism and/or locus of action for mestranol and SKF 525A.4. Examination of plasma levels of pentobarbitone in mice pretreated with mestranol, lynestrenol or SKF 525A showed that lynestrenol increased whilst mestranol and SKF 525A reduced the rate of clearance of barbiturate from the plasma.5. The effects of lynestrenol disappeared when pentobarbitone was prevented from inducing hypothermia, whilst some significant prolongation of pentobarbitone sleep persisted in mestranol treated mice. "
|3.||Heart Diseases (Heart Disease)
12/01/1981 - " According to the most recent studies OC-caused liver tumors happen more often in patients who have taken mestranol for over 4 years; liver tumors are also more common in multiparous women and may grow very quickly during pregnancy. "
03/01/1979 - " More of the OC users who developed benign tumors had used mestranol, results confirming earlier reported associations. "
07/01/1980 - "Malignant tumors were not seen in 33 dogs administered mestranol at 0.02 and 0.05 mg/kg/day for 7 years or in 18 dogs given ethynerone without mestranol at 1.00 mg/kg/day for 5 years. "
07/01/1980 - "Also, 4 dogs that received anagestone acetate plus mestranol at either 0.44 or 1.10 mg/kg/day developed malignant mammary tumors. "
09/01/1977 - " A small number of dogs that received each progestogen-mestranol combination developed clinically malignant tumors; control dogs or dogs that received only mestranol or ethynerone were unaffected. "
|5.||Hypertension (High Blood Pressure)
07/01/1993 - "Because these values were not significantly different, this study provided no evidence that increases in arterial Na content contributed to the hypertension associated with the ingestion of mestranol in this rat model."
10/01/1994 - "However, the pressor responses to NE were significantly less in the mestranol-treated rats than in the controls, indicating that pressor hyper-responsiveness does not contribute to this form of hypertension."
10/01/1994 - "Pressor responsiveness in rats with hypertension induced by mestranol."
07/01/1986 - "Body fluid volumes in rats with mestranol-induced hypertension."
09/01/1986 - "Hypertension was produced in 20 female rats by the oral administration of mestranol for 6 months; 20 control rats were not given mestranol during this time. "
|7.||barbituric acid (barbiturate)
|8.||Ethinyl Estradiol (Estinyl)
|4.||Contraception (Birth Control)